Revolution Medicines Inc
RVMDHealthcare|Biotechnology|USA
$186.89
-4.33 (-2.26%)
Tangible Book
$7.14
About
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Stock Price
+385.4%(1Y)
Pipeline Summary
21 total trials14
Phase 1
9
Phase 2
5
Phase 3
0
Phase 4
Unknown: 1Recruiting: 12Terminated: 2AVAILABLE: 1Completed: 3Active: 2
Active Trials (14)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985Non-small Cell Lung Cancer (NSCLC)
Phase 1Phase 2Recruiting
Enrollment: 754 participants
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC
Phase 1Phase 2Recruiting
Enrollment: 616 participants
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer
Phase 3Recruiting
Enrollment: 900 participants
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591PDAC
Phase 1Phase 2Recruiting
Enrollment: 183 participants
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541Non-small Cell Lung Cancer (NSCLC)
Phase 1Recruiting
Enrollment: 604 participants
BioScore
5.1/10
Watchlist
Ownership
Recent Insider Trades
Patel SushilSELL
2026-06-295,580 shares @ $187.99
Anders JackSELL
2026-06-2420,000 shares @ $168.33
Horn Margaret ASELL
2026-06-1793,575 shares @ $160
Mancini AnthonySELL
2026-06-164,615 shares @ $156.12
GOLDSMITH MARK ASELL
2026-06-1610,020 shares @ $156.12
Recent News
2026-07-09 14:51:18
2026-07-07 13:52:35
2026-07-06 15:45:13
2026-07-06 13:04:54
2026-07-02 19:00:48
Data last updated: Jul 12, 2026, 07:28 PM